88IV - PR Newswire Asia's news - Biotechnology

< Previous page

| Title only | Print

Next page >

Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing ... 2026-07-15T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
ACROBiosystems Obtains PMDA Material Suitability Confirmation for GMP-grade IL-15, Ensuring Reliable Quality and Strengthening the Biopharmaceutical Approval Process NEWARK, Del. , July 15, 2026 /PRNewswire/ -- Recently, ACROBiosystems has officially received the "Material Suitability Confirmation for Regenerative Medicine Products" (Certificate No.: 藥機審長發第47號) ... 2026-07-15T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
NABR: The U.S. Fish and Wildlife Service for the Second Time Rejects Activists' Petition to List Long-Tailed Macaque Monkeys Under the Endangered Species Act WASHINGTON , July 14, 2026 /PRNewswire/ -- On July 14, 2026, the U.S. Fish and Wildlife Service ("USFWS") for the second time declined to accept a petition filed by People for the Ethical ... 2026-07-14T Biotechnology Environmental Products & Services
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor developed from a hit identified via HitGen's DEL technology platform, has advanced into a Phase 2 ... 2026-07-14T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer HONG KONG , July 14, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer ... 2026-07-14T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
STATEMENT FROM THE RIGMORA BIOTECH INVESTORS MONACO , July 14, 2026 /PRNewswire/ -- The Rigmora Biotech Investors welcome the order issued July 10 th 2026 by Hon. Justice Jalil Asif KC of the Grand Court of the Cayman Islands. ... 2026-07-14T Banking/Financial Service Biotechnology Legal issues
Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities SAN DIEGO , July 14, 2026 /PRNewswire/ -- Ahead of the BIO International Convention, BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted ... 2026-07-14T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
HKEY-AI-NAM-Bridge™ 1.0: HKeyBio Connects AI, NAMs and In Vivo Evidence HKEY-AI-NAM-Bridge™ 1.0 connects AI predictions, new approach methodologies and in vivo evidence for more targeted preclinical study design ... 2026-07-13T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Delonix Bioworks Announces First Participant Dosed in Phase 1 Clinical Trial of Next-Generation MenB OMV Vaccine DX-104 in China SHANGHAI , July 13, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, today announced that the first participant has ... 2026-07-13T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Leads Biolabs Announces Multiple Studies Selected for ESMO 2026, Highlighting the Growing Global Competitiveness of Its Core Pipeline NANJING, China , July 13, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that six of its latest research ... 2026-07-13T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved